Venous thromboembolism (including deep vein thrombosis and pulmonary embolism) is a group of diseases with high morbidity. Mortality caused by venous thromboembolism is also highly significant. It is one of the most frequent preventable causes of death in hospital treated patients. It is not easy to assess the real prevalence of the disease because of the frequent symptomless manifestations (as autopsies become less and less frequent, the number of post-mortem diagnoses also decreases) and also because the disease often generates after hospital discharge. There are a number of factors contributing to the development of venous thromboembolism in hospital treated patients. The significance of risk factors differs in the case of patients treated in surgical and medical departments. In this review, the thromboprophylaxis of mainly medical inpatients are discussed. Though there are guidelines about indications and methods of venous thromboprophylaxis, yet it is an unsolved problem to enforce them worldwide and also in Hungary. Despite the effective prophylactic methods, results cannot be considered satisfactory. The number of days spent in hospital and also the number of re-admisson are elevated because of venous thromboembolism. Beside this, the complications also lead to the worsening of the quality of life of these patients, moreover, to disability or death. The financial burden of the health system is also significant. Improvement of the efficacy of the prevention of venous thromboembolism is a highly important issue of health policy. Orv Hetil. 2019; 160(17): 654-661.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1556/650.2019.31338 | DOI Listing |
Eur J Haematol
January 2025
Venous Thromboembolism Unit, Internal Medicine Department, General University Hospital Gregorio Marañón, Madrid, Spain.
Introduction: Anticoagulant therapy is critical for venous thromboembolism (VTE) management, though bleeding remains a major concern, ranging from mild to fatal events. This study aimed to assess the predictive value of cytokines for major bleeding in patients with acute pulmonary embolism (PE).
Methods: In this prospective, observational study, patients aged ≥ 18 years with acute PE were enrolled from April 2021 to September 2022 and followed for 30 days.
Thromb J
January 2025
College of engineering and computer sciences, Jazan University, Jazan, Saudi Arabia.
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), continues to pose significant clinical challenges despite advancements in medical care. Artificial intelligence (AI) presents promising opportunities to enhance the diagnosis, prediction, and management of VTE. This review examines the transformative potential of AI in thrombosis care, highlighting both the potential benefits and the challenges that need to be addressed.
View Article and Find Full Text PDFThromb Res
January 2025
Clinical Investigation Center CIC-EC 1408, University Hospital of Saint-Etienne, France; SAINBIOSE, UMR 1059, INSERM, Jean Monnet University, Saint-Etienne, France; Division of Clinical Hematology, University Hospital of Saint-Etienne, France. Electronic address:
Background: Candidate biomarkers to improve venous thromboembolism (VTE) risk prediction in patients with newly diagnosed multiple myeloma (MM) undergoing anti-myeloma therapy include tissue factor-bearing microvesicles (MV-TF), procoagulant phospholipids (procoag-PPL), and D-dimer.
Objective: We aimed to determine the levels of MV-TF, procoag-PPL, and D-dimer at baseline and during initial anti-myeloma therapy and their association with the risk of VTE.
Methods: This prospective, longitudinal, observational study included 71 patients with newly diagnosed MM who were eligible for anti-myeloma therapy.
J Am Acad Orthop Surg Glob Res Rev
January 2025
From the Department of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT.
Introduction: Venous thromboembolism (VTE) following injury and subsequent fixation of a distal femur fracture (DFFx) is associated with considerable morbidity. However, the incidence of VTE, associated factors, and the relative risk compared with hip fracture (HFx) fixation remains poorly characterized.
Methods: Retrospective cohort study using the PearlDiver M165 database to identify geriatric patients who underwent DFFx and HFx fixation.
Thromb Haemost
January 2025
Guy's and St Thomas' NHS Foundation Trust, King's College London, United Kingdom.
Background: The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) in clinical practice are not well understood.
Methods: ETNA-VTE Europe is a prospective, noninterventional, post-authorization study in unselected patients with VTE treated with edoxaban in eight European countries for up to 18 months. Recurrent VTE, major bleeding, and all-cause death were the primary study outcomes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!